Budesonide / formoterol in treatment of exacerbations of COPD

Study identifier:SD-039-0698

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Effects of high dose inhaled budesonide+ formoterol versus placebo and oral prednisolone on biomarkers of airway inflammation in the treatment of exacerbations in non-hospitalised patients with mild to moderate COPD.

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 2

Healthy volunteers

No

Study drug

budesonide/formoterol, 2x 200/6 microgram. 4 times daily, prednisolone, 30 mg once daily and placebo

Sex

All

Actual Enrollment

120

Study type

Interventional

Age

40 Years +

Date

Study Start Date: 01 Jan 2001
Primary Completion Date: -
Study Completion Date: 01 Jan 2005

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria